Egetis Therapeutics 将来の成長

Future 基準チェック /66

Egetis Therapeutics利益と収益がそれぞれ年間106.4%と81.7%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に26.6% 108%なると予測されています。

主要情報

106.4%

収益成長率

108.0%

EPS成長率

Biotechs 収益成長	45.0%
収益成長率	81.7%
将来の株主資本利益率	26.6%
アナリストカバレッジ	Low
最終更新日	15 Nov 2024

今後の成長に関する最新情報

Recent updates

Is Egetis Therapeutics (STO:EGTX) Using Debt Sensibly?

Aug 20

Here's Why We're Not Too Worried About Egetis Therapeutics' (STO:EGTX) Cash Burn Situation

May 26

Egetis Therapeutics AB (publ) (STO:EGTX) Is Expected To Breakeven In The Near Future

Mar 22

業績と収益の成長予測

OM:EGTX - アナリストの将来予測と過去の財務データ ( )SEK Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	456	93	332	189	5
12/31/2025	325	-3	-141	-41	5
12/31/2024	54	-323	-334	-275	3
9/30/2024	68	-319	-216	-216	N/A
6/30/2024	71	-319	-247	-247	N/A
3/31/2024	63	-327	-254	-254	N/A
12/31/2023	58	-327	-278	-278	N/A
9/30/2023	31	-319	-299	-299	N/A
6/30/2023	24	-286	-249	-249	N/A
3/31/2023	22	-240	-220	-220	N/A
12/31/2022	23	-194	-173	-173	N/A
9/30/2022	20	-148	-137	-137	N/A
6/30/2022	21	-113	-125	-125	N/A
3/31/2022	42	-114	-128	-128	N/A
12/31/2021	38	-104	-130	-130	N/A
9/30/2021	40	-147	-143	-143	N/A
6/30/2021	36	-153	-137	-137	N/A
3/31/2021	33	-155	-133	-133	N/A
12/31/2020	41	-178	-135	-135	N/A
9/30/2020	53	-127	-124	-124	N/A
6/30/2020	56	-134	-134	-134	N/A
3/31/2020	39	-127	-127	-127	N/A
12/31/2019	83	-61	-63	-63	N/A
9/30/2019	77	-61	-54	-54	N/A
6/30/2019	77	-48	-38	-38	N/A
3/31/2019	82	-46	-39	-39	N/A
12/31/2018	28	-85	-81	-81	N/A
9/30/2018	31	-95	-106	-106	N/A
6/30/2018	24	-103	N/A	-97	N/A
3/31/2018	14	-91	N/A	-90	N/A
12/31/2017	14	-88	N/A	-87	N/A
9/30/2017	N/A	-67	N/A	-51	N/A
6/30/2017	0	-48	N/A	-49	N/A
3/31/2017	N/A	-44	N/A	-41	N/A
12/31/2016	N/A	-38	N/A	-36	N/A
9/30/2016	N/A	-36	N/A	-36	N/A
6/30/2016	N/A	-39	N/A	-38	N/A
3/31/2016	N/A	-39	N/A	-44	N/A
12/31/2015	N/A	-44	N/A	-51	N/A
9/30/2015	N/A	-53	N/A	-55	N/A
6/30/2015	N/A	-53	N/A	-52	N/A
3/31/2015	N/A	-54	N/A	-47	N/A
12/31/2014	N/A	-48	N/A	-41	N/A
9/30/2014	N/A	-38	N/A	-34	N/A
6/30/2014	N/A	-31	N/A	-31	N/A
3/31/2014	N/A	-24	N/A	-25	N/A

アナリストによる今後の成長予測

収入対貯蓄率: EGTXは今後 3 年間で収益性が向上すると予測されており、これは貯蓄率 ( 1.2% ) よりも高い成長率であると考えられます。

収益対市場: EGTX今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。

高成長収益: EGTX今後 3 年以内に収益を上げることが予想されます。

収益対市場: EGTXの収益 ( 81.7% ) Swedish市場 ( -0.04% ) よりも速いペースで成長すると予測されています。

高い収益成長: EGTXの収益 ( 81.7% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: EGTXの自己資本利益率は、3年後には高くなると予測されています ( 26.6 %)

Egetis Therapeutics 将来の成長

Future 基準チェック /66

主要情報

今後の成長に関する最新情報

Consensus EPS estimates upgraded to kr0.81 loss, revenue downgraded

Forecast breakeven date moved forward to 2025

Consensus revenue estimates increase by 21%

Price target decreased by 17% to kr11.90

Consensus revenue estimates increase by 13%

Recent updates

Consensus EPS estimates upgraded to kr0.81 loss, revenue downgraded

Forecast breakeven date moved forward to 2025

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Egetis Therapeutics AB (publ), Annual General Meeting, May 06, 2025

New minor risk - Shareholder dilution

Egetis Therapeutics AB (Publ) Announces Resignation of Peder Walberg from the Board of Directors

Egetis Submits A Patent Application to the United States Patent and Trademark Office for Processes of Preparation of Tiratricol

Consensus revenue estimates increase by 21%

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 17% to kr11.90

Egetis Therapeutics AB (publ) to Report Fiscal Year 2024 Results on Feb 26, 2025

Is Egetis Therapeutics (STO:EGTX) Using Debt Sensibly?

Consensus revenue estimates increase by 13%

Egetis Therapeutics AB (publ) Announces Topline Results of the Phase 2 Triac Trial II with Emcitate (Tiratricol) for MCT8 Deficiency

Consensus revenue estimates decrease by 14%, EPS upgraded

Consensus EPS estimates upgraded to kr0.83 loss, revenue downgraded

Consensus revenue estimates increase by 25%

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New major risk - Financial position

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Egetis Therapeutics AB (publ) to Report First Half, 2024 Results on Aug 22, 2024

New minor risk - Share price stability

Price target increased by 11% to kr12.30

Egetis Therapeutics AB (publ) Provides Update on Disease Awareness and the Expanded Access Program for Tiratricol (Emcitate) in the USA

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Egetis Therapeutics AB (publ) to Report Q1, 2024 Results on May 03, 2024

Egetis Therapeutics AB (publ), Annual General Meeting, May 06, 2024

Egetis Therapeutics AB (publ) Announces Ema Validation of Marketing Authorisation Application for Emcitate for the Treatment of Mct8 Deficiency

Egetis Therapeutics AB (publ) Submits Marketing Authorisation Application for Emcitate for Treatment of MCT8 Deficiency to the European Medicines Agency

Egetis Therapeutics AB (publ) to Report Fiscal Year 2023 Results on Feb 24, 2024

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Egetis Therapeutics AB (Publ) Announces First Patient Included and Second Site Activated in the Pivotal Retriact Trial

Chief Executive Officer recently bought kr61k worth of stock

Price target decreased by 8.3% to kr13.30

Forecast breakeven date pushed back to 2025

Independent Director recently bought kr206k worth of stock

Director recently bought kr992k worth of stock

Consensus revenue estimates decrease by 14%, EPS upgraded

Price target decreased by 7.4% to kr14.50

Here's Why We're Not Too Worried About Egetis Therapeutics' (STO:EGTX) Cash Burn Situation

Egetis Terminates Discussions Regarding Potential Acquisition

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Price target increased by 13% to kr17.75

Forecast breakeven date pushed back to 2025

Consensus revenue estimates fall by 16%

Full year 2022 earnings released: kr1.00 loss per share (vs kr0.63 loss in FY 2021)

Egetis Therapeutics AB (Publ) Appoints Katayoun Welin-Berger as Vice President Operations, Effective from March 2023

Egetis Therapeutics AB (publ), Annual General Meeting, Apr 27, 2023

Consensus EPS estimates fall by 15%

We're Keeping An Eye On Egetis Therapeutics' (STO:EGTX) Cash Burn Rate

Egetis Therapeutics AB Submits Expanded Access Program for Emcitate® in the USA

Egetis Therapeutics AB (publ) to Report Fiscal Year 2022 Results on Feb 22, 2023

Less than half of directors are independent

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus forecasts updated

Egetis Therapeutics AB (publ) Receives Positive Opinion on Orphan Designation for Aladote® from the European Medicines Agency for the Prevention of Acute Liver Failure

Forecast breakeven date pushed back to 2024

Egetis Therapeutics AB (Publ) Appoints Sara Melton as President of North America

Egetis Therapeutics AB (Publ) Appoints Sara Melton as President of North America

Will Egetis Therapeutics (STO:EGTX) Spend Its Cash Wisely?

No longer forecast to breakeven

Egetis Therapeutics AB (Publ) Announces Executive Changes

Price target decreased to kr9.00

Less than half of directors are independent

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Egetis Therapeutics AB (Publ) Announces That the Recruitment Target Has Been Met in the Emcitate® Triac Trial II Study

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Egetis Therapeutics AB (publ) Secures Conditional Acceptance for Emcitate® as Brand Name in the US